Urology
Volume 68, Issue 6 , Pages 1152-1155 , December 2006

External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population

  • Dipen J. Parekh

      Affiliations

    • Department of Urology, University of Texas Health Science Center, San Antonio, Texas
    • Corresponding Author InformationReprint requests: Dipen J. Parekh, M.D., Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229.
    • ,
  • Donna Pauler Ankerst

      Affiliations

    • Department of Urology, University of Texas Health Science Center, San Antonio, Texas
    • ,
  • Betsy A. Higgins

      Affiliations

    • Department of Urology, University of Texas Health Science Center, San Antonio, Texas
    • ,
  • Javier Hernandez

      Affiliations

    • Department of Urology, Brooke Army Medical Center, San Antonio, Texas
    • ,
  • Edith Canby-Hagino

      Affiliations

    • Department of Urology, University of Texas Health Science Center, San Antonio, Texas
    • ,
  • Timothy Brand

      Affiliations

    • Department of Urology, University of Texas Health Science Center, San Antonio, Texas
    • ,
  • Dean A. Troyer

      Affiliations

    • Department of Pathology, University of Texas Health Science Center, San Antonio, Texas
    • ,
  • Robin J. Leach

      Affiliations

    • Department of Urology, University of Texas Health Science Center, San Antonio, Texas
    • Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, Texas
    • ,
  • Ian M. Thompson

      Affiliations

    • Department of Urology, University of Texas Health Science Center, San Antonio, Texas

Received 27 September 2006 ,Accepted 19 October 2006.

References 

  1. Chun FK, Graefen M, Briganti A, et al: Initial biopsy outcome prediction—head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol (in press).
  2. Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol. 2003;13:111–116
  3. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–771
  4. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology. 2001;58:843–848
  5. Matsui Y, Egawa S, Tsukayama C, et al. Artificial neural network analysis for predicting pathological stage of clinically localized prostate cancer in the Japanese population. Jpn J Clin Oncol. 2002;32:530–535
  6. Porter CR, Gamito EJ, Crawford ED, et al. Model to predict prostate biopsy outcome in large screening population with independent validation in referral setting. Urology. 2005;65:937–941
  7. Garzotto M, Hudson RG, Peters L, et al. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL. Cancer. 2003;98:1417–1422
  8. Eastham JA, May R, Robertson JL, et al. Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. Urology. 1999;54:709–713
  9. Yanke BV, Carver BS, Bianco FJ, et al. African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram. BJU Int. 2006;98:783–787
  10. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239–2246
  11. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294:66–70
  12. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529–534
  13. Available from http.//www.compass.fhcrc.org/edrnnci/bin/calculator/main.asp. Accessed June 6, 2006.
  14. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224

 This investigation was supported in part by National Cancer Institute U01-CA86402 and the Early Detection Research Network.

PII: S0090-4295(06)02434-4

doi: 10.1016/j.urology.2006.10.022

Urology
Volume 68, Issue 6 , Pages 1152-1155 , December 2006

Article Tools

* Image Usage & Resolution